Key result
ViV TAVI is linked to ~58% lower in-hospital mortality but higher readmissions versus repeat SAVR.
Why the study?
Limited data are available regarding clinical outcomes of ViV TAVI following its FDA approval in 2015 compared with repeat SAVR for failed aortic bioprostheses.
Does valve-in-valve TAVI reduce mortality and readmissions compared to repeat SAVR in patients with a failed aortic bioprosthesis?
Cohort (n=6,769)
Yes
Does valve-in-valve TAVI reduce mortality and readmissions compared to repeat SAVR in patients with a failed aortic bioprosthesis?
In patients with failed aortic bioprostheses, ViV TAVI offers lower in-hospital mortality but is associated with higher short- and intermediate-term readmission rates compared to repeat SAVR.
Answers are grounded in this paper and cite their sources.
ViV TAVI may inform individualized decisions in failed bioprostheses; leaves open net benefit versus repeat SAVR pending randomized trials.
BACKGROUND: Limited data are available regarding clinical outcomes of valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) following the United States Food and Drug Administration approval of ViV TAVI in 2015. AIMS: The aim of this study was to evaluate in-hospital, 30-day, and 6-month outcomes of ViV TAVI versus repeat surgical aortic valve replacement (SAVR) in patients with a failed aortic bioprosthetic valve. METHODS: This retrospective cohort study identified patients who underwent ViV TAVI or repeat SAVR utilising the Nationwide Readmission Database from 2016 to 2018. Primary outcomes were all-cause readmission (at 30 days and 6 months) and in-hospital death. Secondary outcomes were in-hospital stroke, pacemaker implantation, 30-day/6-month major adverse cardiac events (MACE), and mortality during readmission. Propensity score-matching (inverse probability of treatment weighting) analyses were implemented. RESULTS: Out of 6,769 procedures performed, 3,724 (55%) patients underwent ViV TAVI, and 3,045 (45%) underwent repeat SAVR. ViV TAVI was associated with lower in-hospital all-cause mortality (odds ratio [OR] 0.42, 95% confidence interval [CI]: 0.20-0.90, p=0.026) and a higher rate of 30-day (hazard ratio [HR] 1.46, 95% CI: 1.13-1.90, p=0.004) and 6-month all-cause readmission (HR 1.54, 95% CI: 1.14-2.10, p=0.006) compared with repeat SAVR. All secondary outcomes were comparable between the two groups. CONCLUSIONS: ViV TAVI was associated with lower in-hospital mortality but higher 30-day and 6-month all-cause readmission. However, there was no difference in risk of in-hospital stroke, post-procedure pacemaker implantation, MACE, and mortality during 30-day and 6-month readmission compared with repeat SAVR, suggesting that ViV TAVI can be performed safely in carefully selected patients.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a cohort in failed aortic bioprosthetic valve (n=6,769). Valve-in-valve transcatheter aortic valve implantation (ViV TAVI) vs. Repeat surgical aortic valve replacement (SAVR) was evaluated on in-hospital all-cause mortality (OR 0.42, 95% CI 0.20-0.90, p=0.026). ViV TAVI was associated with lower in-hospital all-cause mortality but higher 30-day and 6-month all-cause readmission compared with repeat SAVR.
Synapse has enriched 10 related papers. Consider them for comparative context: